A BuiltForAI Property
Live federal data · NADAC weekly · Part D CY24

Quetiapine Aripiprazole Oral

Quetiapine vs Aripiprazole Oral — $315.0M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Atypical Antipsychotic
Quetiapine
Brand: Quetiapine Fumarate
First FDA approval:
Atypical Antipsychotic
Aripiprazole Oral
Brand: Aripiprazole
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.029Per unit
$0.320Per unit
Average NADACAcross all dosage forms and strengths
$0.749Up to $23.98
$0.320Up to $0.320
Generic manufacturersActive ANDA holders — FDA Orange Book
16132 total ANDAs filed
00 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$315.0MFull year
Full year
Part D claims (CY24)Total fills, all strengths
14.8M2.7M beneficiaries
— beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$21Per claim, all NDCs
Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
794Substantial friction
Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
5Limited friction
None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
NoneClear
Generic availableFDA Orange Book
Yes16 manufacturers
NoBrand-only